Open in Screener

MBX

MBX Biosciences Inc

Aug 15 • 04:00PM ET

14.72

Dollar change +1.51
Percentage change 11.39	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN VTWO SCHA FESM IWC SBIO BBC

Index	RUT	P/E	-	EPS (ttm)	-2.31	Insider Own	55.59%	Shs Outstand	33.59M	Perf Week	21.01%
Market Cap	494.33M	Forward P/E	-	EPS next Y	-2.90	Insider Trans	2.13%	Shs Float	14.92M	Perf Month	20.66%
Enterprise Value	270.09M	PEG	-	EPS next Q	-0.72	Inst Own	57.10%	Short Float	35.81%	Perf Quarter	38.17%
Income	-77.02M	P/S	-	EPS this Y	51.98%	Inst Trans	18.53%	Short Ratio	13.90	Perf Half Y	63.68%
Sales	0.00M	P/B	2.25	EPS next Y	-3.67%	ROA	-52.32%	Short Interest	5.34M	Perf YTD	-20.16%
Book/sh	6.53	P/C	2.20	EPS next 5Y	15.66%	ROE	-56.28%	52W High	27.50 -46.49%	Perf Year	-
Cash/sh	6.70	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-35.05%	52W Low	4.81 206.12%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.90% 13.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.50	EPS Q/Q	-22.16%	SMA20	12.64%	Beta	-	Target Price	37.71
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	20.45%	Rel Volume	1.53	Prev Close	13.21
Employees	43	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	SMA200	12.79%	Avg Volume	384.43K	Price	14.72
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.06% -	Trades		Volume	577,756	Change	11.39%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
08:00AM	Loading…
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:00AM	Loading…
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
04:05PM	Loading…
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM
Mathers Edward T	Director	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:28 PM
BASKETT FOREST	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:26 PM
Behbahani Ali	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:24 PM
Chang Carmen	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:23 PM
Florence Anthony A. Jr.	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:21 PM
Makhzoumi Mohamad	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:20 PM
Walker Paul Edward	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:18 PM
Yang Rick	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:17 PM
SANDELL SCOTT D	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:14 PM
ORBIMED ADVISORS LLC	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:13 PM
New Enterprise Associates 17,	10% Owner	Sep 16 '24	Buy	16.00	500,000	8,000,000	3,614,486	Sep 17 08:12 PM
Frazier Life Sciences X, L.P.	10% Owner	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:11 PM
Heron Patrick J	Director	Sep 16 '24	Buy	16.00	625,000	10,000,000	4,552,774	Sep 17 08:09 PM
Aynechi Tiba	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	2,136,335	Sep 17 08:05 PM
GORDON CARL L	Director	Sep 16 '24	Buy	16.00	750,000	12,000,000	3,158,428	Sep 17 08:05 PM

Open in Screener

KRRO

Korro Bio Inc

Aug 15 • 04:00PM ET

20.26

Dollar change +0.38
Percentage change 1.91	%

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: IWM VTI IWN LFSC VXF VTWO IWC ITOT VHT AVSC

Index	RUT	P/E	-	EPS (ttm)	-9.75	Insider Own	42.87%	Shs Outstand	9.39M	Perf Week	26.63%
Market Cap	190.26M	Forward P/E	-	EPS next Y	-9.77	Insider Trans	0.00%	Shs Float	5.27M	Perf Month	46.49%
Enterprise Value	137.53M	PEG	-	EPS next Q	-2.57	Inst Own	61.21%	Short Float	22.57%	Perf Quarter	39.92%
Income	-91.36M	P/S	30.30	EPS this Y	-7.23%	Inst Trans	7.10%	Short Ratio	8.00	Perf Half Y	-30.33%
Sales	6.28M	P/B	1.65	EPS next Y	2.80%	ROA	-42.49%	Short Interest	1.19M	Perf YTD	-46.78%
Book/sh	12.26	P/C	1.95	EPS next 5Y	-7.79%	ROE	-58.34%	52W High	98.00 -79.33%	Perf Year	-44.28%
Cash/sh	10.37	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-58.07%	52W Low	10.29 96.89%	Perf 3Y	-62.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	27.67%	Volatility	14.36% 11.25%	Perf 5Y	-96.41%
Dividend TTM	-	EV/Sales	21.90	EPS Y/Y TTM	61.73%	Oper. Margin	-1569.08%	ATR (14)	1.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.98	Sales Y/Y TTM	-	Profit Margin	-1454.47%	RSI (14)	70.12	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.98	EPS Q/Q	-12.99%	SMA20	26.15%	Beta	4.82	Target Price	92.33
Payout	-	Debt/Eq	0.39	Sales Q/Q	-	SMA50	41.11%	Rel Volume	0.93	Prev Close	19.88
Employees	104	LT Debt/Eq	0.37	Earnings	Aug 12 BMO	SMA200	-26.00%	Avg Volume	148.69K	Price	20.26
IPO	Oct 03, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-6.80% 200.60%	Trades		Volume	136,740	Change	1.91%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$70
Nov-10-23	Initiated	Piper Sandler	Overweight	$180
Feb-15-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Feb-13-23	Downgrade	Cowen	Outperform → Market Perform
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$12 → $9
Jan-27-21	Upgrade	JP Morgan	Neutral → Overweight	$56
Dec-22-20	Initiated	B. Riley Securities	Buy	$79
Jul-14-20	Initiated	Oppenheimer	Outperform	$36
May-18-20	Downgrade	JP Morgan	Overweight → Neutral	$27
Oct-28-19	Initiated	JP Morgan	Overweight	$25
Oct-28-19	Initiated	Goldman	Buy	$30
Oct-28-19	Initiated	Cowen	Outperform

Show Previous Ratings

Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
07:30AM	Loading…
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
04:01PM	Loading…
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Loading…
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
Aug-12-21 04:06PM	Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm (Newsfile)
08:45AM	Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results (Business Wire)
Aug-04-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Aug-02-21 03:05PM	CLASS ACTION UPDATE for JRVR, FREQ and QFIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders (ACCESSWIRE)
02:30PM	Final Deadline Alert: Frequency Therapeutics, Inc. (FREQ) Class Action and Last Chance for Investors to Actively Participate - Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
12:30PM	SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines (ACCESSWIRE)
12:30PM	FINAL DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
11:00AM	FREQ Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Frequency Therapeutics, Inc. (FREQ) Shareholders of Class Action and Lead Plaintiff Deadline: August 2, 2021 (ACCESSWIRE)
10:00AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ (ACCESSWIRE)
09:16AM	FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Before Important August 2 Deadline in Securities Class Action - FREQ (Newsfile)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Agarwal Vineet	Chief Financial Officer	Nov 11 '24	Option Exercise	11.68	800	9,344	800	Nov 12 07:40 PM
Agarwal Vineet	Chief Financial Officer	Nov 11 '24	Sale	70.00	800	56,000	0	Nov 12 07:40 PM
Agarwal Vineet	Officer	Nov 11 '24	Proposed Sale	70.00	800	56,000		Nov 12 08:28 AM
Agarwal Vineet	Chief Financial Officer	Oct 17 '24	Option Exercise	11.99	10,216	122,468	10,216	Oct 18 07:43 PM
Agarwal Vineet	Chief Financial Officer	Oct 17 '24	Sale	78.26	10,216	799,527	0	Oct 18 07:43 PM
Agarwal Vineet	Officer	Oct 17 '24	Proposed Sale	78.26	10,216	799,527		Oct 17 04:22 PM
Colletti Steve	Former Officer	Oct 16 '24	Proposed Sale	88.67	13,821	1,225,450		Oct 16 01:05 PM
Colletti Steve	Former Officer	Aug 30 '24	Proposed Sale	49.24	10,303	507,326		Aug 30 05:28 PM

Dollar change +5.53
Percentage change 2.83	%

Peers: AMZN MSFT GOOGL ZS CSCO CRWD AKAM OKTA VZ FSLY

| Held by: VTI VO VXF VUG CIBR VOT VGT IWP CGGR IWF

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	11.98%	Shs Outstand	312.68M	Perf Week	-1.80%
Market Cap	70.01B	Forward P/E	180.97	EPS next Y	1.11	Insider Trans	-3.95%	Shs Float	306.73M	Perf Month	5.05%
Enterprise Value	69.51B	PEG	-	EPS next Q	0.23	Inst Own	80.82%	Short Float	3.13%	Perf Quarter	31.49%
Income	-117.08M	P/S	37.21	EPS this Y	14.46%	Inst Trans	2.24%	Short Ratio	2.96	Perf Half Y	13.83%
Sales	1.88B	P/B	56.46	EPS next Y	29.33%	ROA	-2.76%	Short Interest	9.61M	Perf YTD	86.58%
Book/sh	3.56	P/C	17.66	EPS next 5Y	25.14%	ROE	-11.04%	52W High	219.00 -8.26%	Perf Year	145.76%
Cash/sh	11.38	P/FCF	395.49	EPS past 3/5Y	34.82% 8.13%	ROIC	-2.52%	52W Low	74.88 168.31%	Perf 3Y	155.58%
Dividend Est.	-	EV/EBITDA	1214.39	Sales past 3/5Y	36.50% 42.21%	Gross Margin	76.12%	Volatility	3.52% 3.91%	Perf 5Y	443.15%
Dividend TTM	-	EV/Sales	36.95	EPS Y/Y TTM	-11.94%	Oper. Margin	-9.65%	ATR (14)	7.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.14	Sales Y/Y TTM	27.32%	Profit Margin	-6.22%	RSI (14)	53.07	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	5.14	EPS Q/Q	-227.77%	SMA20	-0.08%	Beta	1.95	Target Price	212.00
Payout	-	Debt/Eq	2.79	Sales Q/Q	27.76%	SMA50	4.95%	Rel Volume	0.65	Prev Close	195.38
Employees	4263	LT Debt/Eq	2.75	Earnings	Jul 31 AMC	SMA200	43.39%	Avg Volume	3.25M	Price	200.91
IPO	Sep 13, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.50% 2.20%	Trades		Volume	2,121,894	Change	2.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	KeyBanc Capital Markets	Overweight
Apr-16-25	Upgrade	Mizuho	Neutral → Outperform	$135
Mar-25-25	Upgrade	BofA Securities	Underperform → Buy	$160
Mar-20-25	Resumed	Oppenheimer	Outperform	$150
Mar-18-25	Resumed	Morgan Stanley	Overweight
Feb-11-25	Downgrade	DZ Bank	Hold → Sell	$145
Feb-07-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-03-25	Downgrade	Robert W. Baird	Outperform → Neutral	$125 → $140
Jan-17-25	Upgrade	Citigroup	Neutral → Buy	$95 → $145
Jan-17-25	Initiated	Cantor Fitzgerald	Neutral	$111
Jan-03-25	Reiterated	RBC Capital Mkts	Outperform	$99 → $123
Jan-02-25	Upgrade	Goldman	Sell → Buy	$77 → $140
Dec-17-24	Upgrade	Stifel	Hold → Buy	$95 → $136
Dec-02-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-08-24	Initiated	Exane BNP Paribas	Underperform	$65
Jul-16-24	Initiated	Wolfe Research	Peer Perform
Jul-08-24	Initiated	Scotiabank	Sector Perform	$85
Jun-25-24	Upgrade	UBS	Sell → Neutral	$76 → $82
May-07-24	Upgrade	DZ Bank	Hold → Buy	$95
Feb-13-24	Downgrade	DZ Bank	Buy → Hold	$110

Show Previous Ratings

Aug-15-25 01:05PM	JMP Lifts PT for Cloudflare (NET), Keeps Market Outperform Rating (Insider Monkey)
10:00AM	Meet the first batch of VCs set to judge Startup Battlefield 200 at TechCrunch Disrupt 2025 (TechCrunch)
09:00AM	Is Trending Stock Cloudflare, Inc. (NET) a Buy Now? (Zacks)
Aug-14-25 04:45PM	Cloudflare, Commvault Systems, Sprinklr, F5, and HubSpot Stocks Trade Down, What You Need To Know (StockStory)
04:26PM	Cloudflare, Inc. (NET) "Is By Far My Favorite," Says Jim Cramer (Insider Monkey)
07:52AM	Loading…
07:52AM	North America Web Application Firewall Market Growth Trends Report 2025-2033 \| E-commerce and Digital Services Drive Demand for Robust Web Application Firewalls (GlobeNewswire)
Aug-13-25 12:33AM	1 High-Flying Stock Worth Your Attention and 2 Facing Challenges (StockStory)
Aug-12-25 11:52PM	Cloudflare, Inc. (NET) Reports Second-Quarter Results; Scotiabank Raises PT to $200 (Insider Monkey)
10:51PM	NET Q2 Deep Dive: Large Customer Expansion and AI Strategy Highlight Cloudflare's Progress (StockStory)
10:50PM	5 Revealing Analyst Questions From Cloudflare's Q2 Earnings Call (StockStory)
12:59AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
Aug-11-25 12:00PM	Inside the looming AI-agents war that will redefine the economics of the web (FastCompany)
Aug-07-25 11:49PM	Jim Cramer on Cloudflare: " These Guys Delivered a Clean Beat and Raise Quarter" (Insider Monkey)
03:52PM	Fortinet Falls On Q2 Results. Investors 'Confused' On Firewall Refresh. Cybersecurity Stocks Sell Off. (Investor's Business Daily)
Aug-06-25 10:19PM	Mizuho Raised the Firm's PT on Cloudflare (NET), Kept a Buy Rating (Insider Monkey)
09:38AM	Loading…
09:38AM	The Fed's Inflation Conundrum & an AI Billionaire Battle Royale (Motley Fool)
Aug-05-25 12:33PM	Some people are defending Perplexity after Cloudflare named and shamed it (TechCrunch)
12:13PM	Cloudflare vs. Perplexity: a web scraping war with big implications for AI (FastCompany)
08:38AM	Do You Believe in the Strong Fundamentals of Cloudflare (NET)? (Insider Monkey)
12:36AM	1 Large-Cap Stock to Own for Decades and 2 We Question (StockStory)
Aug-04-25 06:48PM	Cloudflare Accuses Perplexity AI of Using Stealth Crawlers to Evade Website Blocks (decrypt)
11:41AM	Perplexity accused of scraping websites that explicitly blocked AI scraping (TechCrunch)
09:00AM	Is Most-Watched Stock Cloudflare, Inc. (NET) Worth Betting on Now? (Zacks)
Aug-01-25 11:41AM	Cloudflare Q2 Earnings and Revenues Beat Estimates, FY25 View Raised (Zacks)
11:06AM	Cloudflare, Inc. (NET) Hits New 52-Week High; UBS and Baird Raise PT (Insider Monkey)
09:31AM	Analyst Report: Cloudflare, Inc. (Morningstar Research)
09:22AM	Stock Market Today: Dow Tumbles On New Trump Tariffs, Weak Jobs Report; Amazon Plunges On Earnings (Live Coverage) (Investor's Business Daily)
08:12AM	Stock Market Today: Dow Falls On New Trump Tariffs, Jobs Report Next; Amazon Plunges On Earnings (Live Coverage) (Investor's Business Daily)
08:00AM	Missed The AI Bonanza? 12 Stocks Drive The Coming Quantum Boom (Investor's Business Daily)
Jul-31-25 07:38PM	Cloudflare Earnings: Big Deals and AI (Motley Fool)
05:35PM	Loading…
05:35PM	Cloudflare (NET) Tops Q2 Earnings and Revenue Estimates (Zacks)
05:04PM	Apple, Amazon, Coinbase: Stocks to Watch Afterhours (The Wall Street Journal)
04:42PM	Cloudflare's (NYSE:NET) Q2 Sales Beat Estimates, Stock Soars (StockStory)
04:34PM	Cloudflare Earnings Beat On Big Deal Growth. Guidance Above Views. (Investor's Business Daily)
04:30PM	Cloudflare: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Cloudflare Announces Second Quarter 2025 Financial Results (Business Wire)
01:43PM	Apple Rebound Looks Elusive as AI Woes Draw Investor Scrutiny (Bloomberg)
Jul-30-25 11:59PM	Citizens JMP Lifts Cloudflare (NET) PT to $225 as Analysts Eye AI Opportunity (Insider Monkey)
04:05PM	Pipe Firestarter Storage Launches, Making the Pipe Network a Full Stack Cloudflare Alternative on Solana (PR Newswire)
07:01AM	How Cloudflare declared war on AI scrapers (FastCompany)
Jul-29-25 11:21PM	Cloudflare Earnings: What To Look For From NET (StockStory)
10:00AM	Porch Group, Inc. (PRCH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
02:06AM	Cloudflare Gets $225 Target from Wells Fargo on Enterprise Surge (Insider Monkey)
Jul-28-25 08:54PM	Analysts reboot Cloudflare stock price target ahead of earnings (TheStreet)
03:09PM	Outage Hits Microsoft Windows, Disrupting Flights, Cities and Businesses (The Wall Street Journal)
11:36AM	Cloudflare to Post Q2 Earnings: Time to Buy, Sell or Hold the Stock? (Zacks)
09:15AM	What Makes Cloudflare (NET) a Compelling Long-Term Compounder? (Insider Monkey)
Jul-25-25 07:00PM	The New Chips Designed to Solve AIs Energy Problem (The Wall Street Journal)
02:25PM	Why Cloudflare (NET) Stock Is Up Today (StockStory)
Jul-24-25 10:02AM	Fortune Announces Speakers for 2025 Brainstorm Tech September 8 - 10 (PR Newswire)
10:00AM	Earnings Preview: Cloudflare (NET) Q2 Earnings Expected to Decline (Zacks)
08:58AM	Strong Results Boosted Cloudflare (NET) in Q2 (Insider Monkey)
Jul-23-25 12:31AM	1 Volatile Stock to Target This Week and 2 Facing Headwinds (StockStory)
Jul-22-25 06:00PM	Cloudflare (NET) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
07:00AM	Google Seeks Licensing Talks With News Groups, Following AI Rivals (Bloomberg)
Jul-21-25 09:00AM	Cloudflare, Inc. (NET) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Jul-19-25 04:00AM	Staying hands on made scaling to $1B+ fun for Cloudflares founder (FastCompany)
Jul-18-25 02:30PM	Jim Cramer on Cloudflare: "The Stock Should Be Bought Even Up Here" (Insider Monkey)
12:00PM	3 Words That Could Be a Big Problem for Artificial Intelligence (AI) Chatbots (Motley Fool)
09:20AM	NET Surges 87.3% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
Jul-17-25 10:00AM	Hydrolix Adds Support for Cloudflare HTTP Logs, Delivering Real-Time, Full-Fidelity Visibility at Scale (PR Newswire)
09:00AM	Lasso Unveils GenAI Security Cloudflare Integration for Real-Time Monitoring and Protection (Business Wire)
Jul-16-25 09:00AM	Versa SSE Achieves Recommended Rating and 99.98% Security Effectiveness from CyberRatings.org in Testing by NSS Labs (Business Wire)
08:23AM	How Cloudflare CEO Prince Turned Company Into Internet's 'Swiss Army Knife' (Investor's Business Daily)
06:00AM	CyberRatings.org Test Results Reveal Critical Failures in SSE (PR Newswire)
12:35AM	2 Cash-Producing Stocks with Impressive Fundamentals and 1 to Keep Off Your Radar (StockStory)
Jul-15-25 05:50PM	Why the Market Dipped But Cloudflare (NET) Gained Today (Zacks)
Jul-14-25 01:14PM	FSLY Stock is Slipping: Can a Steady Enterprise Base Hold the Stock? (Zacks)
04:00AM	The era of free AI scraping may be coming to an end (FastCompany)
Jul-11-25 02:48PM	Nvidia Drives AI Stampede With Broadcom, Palantir And More In Tow (Investor's Business Daily)
12:34PM	CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins? (MarketBeat)
Jul-10-25 06:00PM	Cloudflare (NET) Stock Dips While Market Gains: Key Facts (Zacks) -5.98%
12:35PM	Cloudflare vs. Fastly: Which Stock Has the Edge on CDN Space? (Zacks)
02:19AM	TD Cowen Hikes Cloudflare (NET) Price Target, Cites Strong Demand Despite Macroeconomic Concerns (Insider Monkey)
Jul-09-25 06:20AM	Bear of the Day: Cloudflare (NET) (Zacks)
04:47AM	Taiwan Semiconductor and Cloudflare have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Jul-08-25 04:15PM	Cloudflare Announces Date of Second Quarter 2025 Financial Results (Business Wire)
02:46PM	Jobs, Cars, AI, and Financial Freedom (Motley Fool)
10:35AM	Cloudflare Improves Sales Execution: Will Margin Gain Continue? (Zacks)
09:00AM	Cloudflare, Inc. (NET) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
12:36AM	1 Cash-Heavy Stock Worth Your Attention and 2 to Turn Down (StockStory)
Jul-07-25 04:29PM	Cloudflare, Inc. (NET): A Bull Case Theory (Insider Monkey)
08:50AM	How to Find Strong Computer and Technology Stocks Slated for Positive Earnings Surprises (Zacks)
07:50AM	Will Cybersecurity Stocks Out-Perform As Earnings Reports Loom? (Investor's Business Daily)
Jul-06-25 03:48AM	Cloudflare Launches AI Crawler Blocking and "Pay Per Crawl" Model (Insider Monkey)
Jul-05-25 10:00AM	ALL4 Mining: Certified Leader in Secure Crypto Cloud Mining Launches New Mobile App (GlobeNewswire)
Jul-04-25 12:11PM	FSLY Expands Security Offerings: Will This Move Pay Off for the Stock? (Zacks)
Jul-03-25 12:09PM	CrowdStrike, Cloudflare Stock Cashing In As Cybersecurity Needs Grow (Investor's Business Daily)
08:09AM	Do You Believe in the Growth Potential of Cloudflare (NET)? (Insider Monkey)
Jul-02-25 01:37AM	The Top 5 Analyst Questions From Cloudflare's Q1 Earnings Call (StockStory)
Jul-01-25 06:00PM	Cloudflare (NET) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks) -5.56%
04:25PM	Cloudflare CEO: Need to monetize the AI-driven web (CNBC TV)
03:33PM	Cloudflare Blocks AI Bots by Default (GuruFocus.com)
10:15AM	Cloudflare Stock Just Hit a New High, But Dont Count on More Upside (Barchart)
07:45AM	Goldman rolls out latest U.S. Conviction List update (Investing.com)
06:33AM	Cloudflare Targets Media Firms, Content Creators Amid AI Boom (Investor's Business Daily)
06:05AM	Cloudflare launches tool to help website owners monetize AI bot crawler access (Reuters)
06:00AM	Cloudflare launches a marketplace that lets websites charge AI bots for scraping (TechCrunch)
06:00AM	Cloudflare Just Changed How AI Crawlers Scrape the Internet-at-Large; Permission-Based Approach Makes Way for A New Business Model (Business Wire)
04:05AM	Billionaires Sell Tesla Stock and Buy Another AI Stock Up 327% in 3 Years (Motley Fool)

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kramer Douglas James	CHIEF LEGAL OFFICER	Aug 01 '25	Sale	198.22	3,000	594,663	157,377	Aug 04 04:50 PM
DOUGLAS KRAMER	Officer	Aug 01 '25	Proposed Sale	198.22	3,000	594,663		Aug 01 04:04 PM
SEIFERT THOMAS J	Chief Financial Officer	Jul 28 '25	Sale	200.30	59,130	11,843,987	0	Jul 29 05:49 PM
SEIFERT THOMAS J	Chief Financial Officer	Jul 25 '25	Sale	200.00	1,600	320,000	0	Jul 29 05:49 PM
Ledbetter Carl	Director	Jul 28 '25	Sale	199.85	15,000	2,997,692	1,043,073	Jul 29 05:45 PM
CENTER COURT PARTNERS LTD	Officer	Jul 28 '25	Proposed Sale	198.42	40,911	8,117,561		Jul 28 04:15 PM
CENTER COURT 2020 TRUST 2	Officer	Jul 28 '25	Proposed Sale	198.42	5,600	1,111,152		Jul 28 04:14 PM
CENTER COURT 2020 TRUST 3 U/A	Officer	Jul 28 '25	Proposed Sale	198.42	6,362	1,262,348		Jul 28 04:12 PM
CENTER COURT 2020 TRUST 1	Officer	Jul 28 '25	Proposed Sale	198.42	6,257	1,241,514		Jul 28 04:12 PM
CENTER COURT 2020 TRUST 1	Officer	Jul 25 '25	Proposed Sale	191.58	400	76,632		Jul 25 04:17 PM
CENTER COURT 2020 TRUST 3 U/A	Officer	Jul 25 '25	Proposed Sale	191.58	400	76,632		Jul 25 04:17 PM
CENTER COURT 2020 TRUST 2	Officer	Jul 25 '25	Proposed Sale	191.58	400	76,632		Jul 25 04:17 PM
CENTER COURT PARTNERS LTD	Officer	Jul 25 '25	Proposed Sale	191.58	400	76,632		Jul 25 04:17 PM
SEIFERT THOMAS J	Chief Financial Officer	Jul 21 '25	Sale	200.17	34,270	6,859,883	0	Jul 22 07:22 PM
SEIFERT THOMAS J	Chief Financial Officer	Jul 21 '25	Sale	198.13	10,000	1,981,295	241,550	Jul 22 07:22 PM
THOMAS SEIFERT	Officer	Jul 21 '25	Proposed Sale	197.35	10,000	1,973,500		Jul 21 04:27 PM
CENTER COURT 2020 TRUST 1	Officer	Jul 21 '25	Proposed Sale	197.35	8,343	1,646,491		Jul 21 04:26 PM
CENTER COURT 2020 TRUST 3 U/A	Officer	Jul 21 '25	Proposed Sale	197.35	8,238	1,625,769		Jul 21 04:25 PM
CENTER COURT 2020 TRUST 2	Officer	Jul 21 '25	Proposed Sale	197.35	9,000	1,776,150		Jul 21 04:25 PM
CENTER COURT PARTNERS LTD	Officer	Jul 21 '25	Proposed Sale	197.35	8,689	1,714,774		Jul 21 04:25 PM
Zatlyn Michelle	President and Board Co-Chair	Jul 17 '25	Sale	190.68	25,641	4,889,348	6,390	Jul 17 07:51 PM
Zatlyn Michelle	President and Board Co-Chair	Jul 16 '25	Sale	187.32	25,641	4,802,963	6,390	Jul 17 07:51 PM
Zatlyn Michelle	President and Board Co-Chair	Jul 15 '25	Sale	182.80	25,641	4,687,138	6,390	Jul 17 07:51 PM
Prince Matthew	CEO & Board Co-Chair	Jul 09 '25	Sale	194.45	52,384	10,185,818	0	Jul 10 09:09 PM
Prince Matthew	CEO & Board Co-Chair	Jul 08 '25	Sale	192.27	52,384	10,071,925	0	Jul 10 09:09 PM
Prince Matthew	CEO & Board Co-Chair	Jul 10 '25	Sale	184.58	52,384	9,669,079	0	Jul 10 09:09 PM
Kramer Douglas James	Chief Legal Officer	Jul 01 '25	Sale	196.09	9,000	1,764,815	160,377	Jul 02 08:34 PM
Ledbetter Carl	Director	Jun 30 '25	Sale	193.94	15,000	2,909,059	1,058,073	Jul 01 06:14 PM
DOUGLAS KRAMER	Officer	Jul 01 '25	Proposed Sale	196.09	9,000	1,764,814		Jul 01 04:16 PM
Ledbetter Carl	Director	Jun 30 '25	Proposed Sale	193.94	60,000	11,636,238		Jun 30 04:08 PM
SEIFERT THOMAS J	Chief Financial Officer	Jun 20 '25	Sale	180.76	10,000	1,807,588	241,550	Jun 23 05:15 PM
THOMAS SEIFERT	Officer	Jun 20 '25	Proposed Sale	181.40	10,000	1,814,000		Jun 20 04:24 PM
Ledbetter Carl	Director	Jun 17 '25	Sale	181.57	10,050	1,824,806	1,073,073	Jun 18 05:04 PM
Prince Matthew	CEO & Board Co-Chair	Jun 11 '25	Sale	179.63	52,384	9,409,824	0	Jun 13 08:29 PM
Prince Matthew	CEO & Board Co-Chair	Jun 12 '25	Sale	176.39	52,384	9,239,781	0	Jun 13 08:29 PM
Prince Matthew	CEO & Board Co-Chair	Jun 13 '25	Sale	171.25	52,384	8,970,603	0	Jun 13 08:29 PM
Ledbetter Carl	Director	Jun 11 '25	Sale	181.46	749	135,912	1,083,615	Jun 13 06:43 PM
Ledbetter Carl	Director	Jun 12 '25	Sale	181.46	492	89,281	1,083,123	Jun 13 06:43 PM
Matthew Prince	Officer	Jun 11 '25	Proposed Sale	179.71	471,456	84,725,358		Jun 11 05:15 PM
Ledbetter Carl	Director	Jun 11 '25	Proposed Sale	181.46	11,291	2,048,837		Jun 11 04:34 PM
Suder Katrin	Director	Jun 05 '25	Sale	172.00	608	104,576	41,785	Jun 09 04:23 PM
Zatlyn Michelle	President and Board Co-Chair	Jun 06 '25	Sale	178.50	25,641	4,577,000	6,390	Jun 06 07:52 PM
Zatlyn Michelle	President and Board Co-Chair	Jun 04 '25	Sale	173.00	25,642	4,435,981	6,390	Jun 06 07:52 PM
Zatlyn Michelle	President and Board Co-Chair	Jun 05 '25	Sale	171.41	25,641	4,395,196	6,390	Jun 06 07:52 PM
KATRIN SUSANNE SUDER	Director	Jun 05 '25	Proposed Sale	172.00	608	104,576		Jun 05 04:13 PM
Michelle Zatlyn	Officer	Jun 04 '25	Proposed Sale	170.92	153,847	26,295,529		Jun 04 04:46 PM
Kramer Douglas James	Chief Legal Officer	Jun 02 '25	Sale	166.00	3,000	498,014	169,377	Jun 02 06:18 PM
DOUGLAS KRAMER	Officer	Jun 02 '25	Proposed Sale	166.00	3,000	498,014		Jun 02 04:29 PM
Zatlyn Michelle	President and Board Co-Chair	May 20 '25	Sale	156.83	35,098	5,504,251	6,390	May 22 08:06 PM
Zatlyn Michelle	President and Board Co-Chair	May 22 '25	Sale	157.10	25,640	4,028,045	6,390	May 22 08:06 PM
Zatlyn Michelle	President and Board Co-Chair	May 21 '25	Sale	156.72	25,640	4,018,321	6,390	May 22 08:06 PM
SEIFERT THOMAS J	Chief Financial Officer	May 20 '25	Sale	156.78	41,556	6,515,117	241,550	May 22 04:10 PM
Michelle Zatlyn	Officer	May 20 '25	Proposed Sale	157.42	86,378	13,597,625		May 20 05:08 PM
THOMAS J SEIFERT	Officer	May 20 '25	Proposed Sale	157.52	41,556	6,545,901		May 20 04:28 PM
Riley Janel	Chief Accounting Officer	May 16 '25	Sale	154.80	3,488	539,953	67,363	May 16 04:22 PM
Prince Matthew	CEO & Board Co-Chair	May 15 '25	Sale	152.68	52,384	7,997,995	10,426	May 15 08:24 PM
Prince Matthew	CEO & Board Co-Chair	May 14 '25	Sale	152.58	52,384	7,992,506	0	May 15 08:24 PM
Prince Matthew	CEO & Board Co-Chair	May 13 '25	Sale	148.85	52,384	7,797,333	0	May 15 08:24 PM
Matthew Prince	Officer	May 13 '25	Proposed Sale	150.36	157,152	23,629,375		May 13 05:13 PM
Kramer Douglas James	Chief Legal Officer	May 01 '25	Sale	124.16	3,000	372,486	185,406	May 01 04:34 PM
DOUGLAS KRAMER	Officer	May 01 '25	Proposed Sale	124.16	3,000	372,485		May 01 04:02 PM
SEIFERT THOMAS J	Chief Financial Officer	Apr 25 '25	Sale	120.14	10,000	1,201,354	293,582	Apr 28 04:18 PM
THOMAS J SEIFERT	Officer	Apr 25 '25	Proposed Sale	118.87	10,000	1,188,700		Apr 25 04:24 PM
Zatlyn Michelle	President and Board Co-Chair	Apr 16 '25	Sale	110.36	25,640	2,829,650	0	Apr 17 09:14 PM
Zatlyn Michelle	President and Board Co-Chair	Apr 17 '25	Sale	109.03	25,640	2,795,417	0	Apr 17 09:14 PM
Zatlyn Michelle	President and Board Co-Chair	Apr 15 '25	Sale	107.29	25,640	2,751,034	0	Apr 17 09:14 PM
Prince Matthew	CEO & Board Co-Chair	Apr 10 '25	Sale	107.75	2,311	249,016	0	Apr 10 08:33 PM
Prince Matthew	CEO & Board Co-Chair	Apr 09 '25	Sale	104.05	52,384	5,450,501	0	Apr 10 08:27 PM
Prince Matthew	CEO & Board Co-Chair	Apr 10 '25	Sale	105.59	50,073	5,287,188	2,311	Apr 10 08:27 PM
Prince Matthew	CEO & Board Co-Chair	Apr 08 '25	Sale	100.88	52,384	5,284,686	0	Apr 10 08:27 PM
Kramer Douglas James	Chief Legal Officer	Apr 01 '25	Sale	112.83	9,000	1,015,507	188,406	Apr 01 04:48 PM
DOUGLAS KRAMER	Officer	Apr 01 '25	Proposed Sale	112.83	9,000	1,015,506		Apr 01 04:09 PM
Zatlyn Michelle	President and Board Co-Chair	Mar 25 '25	Sale	130.85	25,640	3,355,108	0	Mar 27 07:04 PM
Zatlyn Michelle	President and Board Co-Chair	Mar 26 '25	Sale	125.91	25,640	3,228,362	0	Mar 27 07:04 PM
Zatlyn Michelle	President and Board Co-Chair	Mar 27 '25	Sale	117.34	25,640	3,008,721	0	Mar 27 07:04 PM
SEIFERT THOMAS J	CHIEF FINANCIAL OFFICER	Mar 20 '25	Sale	120.00	10,000	1,200,000	293,582	Mar 21 04:19 PM
THOMAS J SEIFERT	Officer	Mar 20 '25	Proposed Sale	117.58	10,000	1,175,800		Mar 20 04:20 PM
Prince Matthew	CEO & Board Co-Chair	Mar 19 '25	Sale	117.32	52,384	6,145,622	0	Mar 19 07:22 PM
Prince Matthew	CEO & Board Co-Chair	Mar 17 '25	Sale	116.47	52,384	6,100,932	0	Mar 19 07:22 PM
Prince Matthew	CEO & Board Co-Chair	Mar 18 '25	Sale	113.72	52,384	5,957,115	0	Mar 19 07:22 PM
THOMAS J SEIFERT	Officer	Mar 05 '25	Proposed Sale	140.93	15,000	2,113,950		Mar 05 04:22 PM
DOUGLAS KRAMER	Officer	Mar 05 '25	Proposed Sale	140.06	3,000	420,180		Mar 05 04:06 PM
Prince Matthew	CEO & Board Co-Chair	Feb 26 '25	Sale	145.71	52,384	7,632,973	0	Feb 27 09:02 PM
Prince Matthew	CEO & Board Co-Chair	Feb 27 '25	Sale	145.04	52,384	7,597,627	0	Feb 27 09:02 PM
Prince Matthew	CEO & Board Co-Chair	Feb 25 '25	Sale	143.39	52,384	7,511,249	0	Feb 27 09:02 PM
Suder Katrin	Director	Feb 25 '25	Sale	145.82	9,941	1,449,596	41,221	Feb 27 04:06 PM
Matthew Prince	Officer	Feb 25 '25	Proposed Sale	143.14	471,456	67,484,212		Feb 25 05:29 PM
KATRIN SUSANNE SUDER	Director	Feb 25 '25	Proposed Sale	145.82	9,941	1,449,595		Feb 25 04:09 PM
Zatlyn Michelle	President and Board Co-Chair	Feb 19 '25	Sale	164.84	35,099	5,785,547	0	Feb 21 09:20 PM
Zatlyn Michelle	President and Board Co-Chair	Feb 20 '25	Sale	156.91	25,640	4,023,254	0	Feb 21 09:20 PM
Zatlyn Michelle	President and Board Co-Chair	Feb 21 '25	Sale	156.67	25,640	4,016,929	0	Feb 21 09:20 PM
Riley Janel	Chief Accounting Officer	Feb 18 '25	Sale	167.60	4,327	725,196	74,698	Feb 19 06:16 PM
SEIFERT THOMAS J	Chief Financial Officer	Feb 19 '25	Sale	162.07	28,635	4,640,912	293,582	Feb 19 06:14 PM
Michelle Zatlyn	Officer	Feb 19 '25	Proposed Sale	160.59	240,219	38,576,769		Feb 19 04:52 PM
THOMAS J SEIFERT	Officer	Feb 19 '25	Proposed Sale	168.81	28,635	4,833,874		Feb 19 04:30 PM
SEIFERT THOMAS J	Chief Financial Officer	Feb 03 '25	Sale	136.63	15,000	2,049,447	252,869	Feb 05 06:39 PM
Kramer Douglas James	Chief Legal Officer	Feb 03 '25	Sale	131.66	2,481	326,648	175,688	Feb 05 06:00 PM
THOMAS J SEIFERT	Officer	Feb 03 '25	Proposed Sale	138.40	15,000	2,076,000		Feb 03 04:18 PM
DOUGLAS KRAMER	Officer	Feb 03 '25	Proposed Sale	131.66	2,481	326,648		Feb 03 04:07 PM
Zatlyn Michelle	President and COO	Jan 24 '25	Sale	123.75	25,640	3,172,847	0	Jan 24 08:09 PM

MBX

MBX Biosciences Inc

KRRO

Korro Bio Inc

NET

Cloudflare Inc

Upgrade your FINVIZ experience